Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

BenevolentAI S.A.. (6/4/24). "Press Release: BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference".

Organisations Organisation BenevolentAI S.A. (Euronext Amsterdam: BAI)
  Group BenevolentAI (Group)
  Organisation 2 FTI Consulting, London (Aldersgate)
  Group FTI Consulting (Group)
Products Product Goldman Sachs Annual Global Healthcare Conference 2024 Miami
  Product 2 Benevolent Platform®
Index terms Index term BenevolentAI–Goldman Sachs: investor conference, 202406 supply service BenevolentAI at GS Annual Global Healthcare Conference
  Index term 2 BenevolentAI–FTI Consulting: public relations, 202309 service existent by FTI Consulting
Persons Person Möller, Jörg (BenevolentAI 202401– CEO before Leo Pharma + Bayer 201403–202012)
  Person 2 Isted, Catherine (BenevolentAI 202309– CFO before ReNeuron + Oxford Biomedica + Morgan Stanley + ABN AMRO + Nomura)

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, 11-13 June 2024 in Miami, US.

Dr Joerg Moeller MD, Chief Executive Officer, and Catherine Isted ACMA, Chief Financial Officer, are scheduled to take part in a fireside chat at 08:40 EDT (13:40 BST) on 13 June 2024.

They will also be available throughout the conference for meetings on-site and adjacent to the programme (see contact details below).

About BenevolentAI

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platform™ that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.

The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck and advancing in-house pipelines to inflection points. Headquartered in London, with wet labs in Cambridge (UK), BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Category: non-regulatory


Catherine Isted – Chief Financial Officer

James Osborn – Communications Lead

FTI Consulting:
Ben Atwell/Simon Conway/Victoria Foster Mitchell
T: +44 203 727 1000

Record changed: 2024-06-21


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for BenevolentAI (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Consultech GmbH Secure Funding with RnD Grants 650x300px

» top